论文部分内容阅读
目的探讨不同剂量阿托伐他汀在短暂性脑缺血发作(TIA)治疗和二级预防中的应用效果。方法 2008年1月-2008年10月TIA患者90例随机分为观察组和对照组各45例,两组均实施TIA常规治疗,对照组同时给予阿托伐他汀10 mg/d;观察组应用阿托伐他汀20 mg/d。结果两组患者近期治疗效果差异无统计学意义(P>0.05);随访12~54个月,平均(26.34±8.56)个月,观察组TIA复发次数少、脑梗死比例低(P<0.05)。两组药物不良反应比较差异无统计学意义(P>0.05),无需停用阿托伐他汀,未发现过敏反应及脑出血病例,无肾功能损害。结论在综合治疗的基础上应用20 mg阿托伐他汀比常规剂量10 mg有较好且安全的疗效。
Objective To investigate the effect of different doses of atorvastatin in the treatment of TIA and secondary prevention. Methods From January 2008 to October 2008, 90 TIA patients were randomly divided into observation group (45 cases) and control group (45 cases). Both groups were given conventional TIA treatment and atorvastatin 10 mg / d in the control group. The observation group Atorvastatin 20 mg / d. Results There was no significant difference in short-term treatment effect between the two groups (P> 0.05). The follow-up ranged from 12 to 54 months (mean, 26.34 ± 8.56) months. . There was no significant difference in adverse drug reactions between the two groups (P> 0.05), no need to stop atorvastatin, no allergic reaction and cerebral hemorrhage, and no renal damage. Conclusion At the basis of comprehensive treatment, 20 mg atorvastatin is better and safer than 10 mg conventional dose.